Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.

Autor: Delphine Degré, Thomas Sersté, Luc Lasser, Jean Delwaide, Peter Starkel, Wim Laleman, Philippe Langlet, Hendrik Reynaert, Stefan Bourgeois, Thomas Vanwolleghem, Sergio Negrin Dastis, Thierry Gustot, Anja Geerts, Christophe Van Steenkiste, Chantal de Galocsy, Antonia Lepida, Hans Orlent, Christophe Moreno

Publikováno v: PLoS ONE, Vol 12, Iss 1, p e0170933 (2017)

INTRODUCTION:Hepatitis C virus (HCV) is a major global health issue and successful treatment has been associated with a reduction of risk of all-cause mortality. Advancements have been made in HCV treatment through the use of interferon-free regimens

Externí odkaz: https://doaj.org/article/cdb05ce6ce7742ddab32d7fd141c2fc6

Non-invasive diagnosis and follow-up of portal hypertension

Autor: Victor de Lédinghen, Thomas Sersté, Christophe Bureau, Marika Rudler, Dominique Thabut, Nathalie Ganne-Carrié, Delphine Weil, Charlotte Bouzbib, Laurent Castera, Christophe Cassinotto, Frédéric Oberti, M. Bourlière

Publikováno v: Clinics and Research in Hepatology and Gastroenterology
Clinics and Research in Hepatology and Gastroenterology, 2022, 46 (8), pp.101767. ⟨10.1016/j.clinre.2021.101767⟩

Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis/cirrhosis in asymptomatic patients at risk of developing clinically significant portal hypertension (CSPH, defined by a hepatic venous pressure gradient (H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cb9fe6b34441779db973812ba272d94
https://www.hal.inserm.fr/inserm-04048906

Epigenetic basis for monocyte dysfunction in patients with severe alcoholic hepatitis

Autor: Kinga K. Smolen, Christophe Moreno, Abdulkader Azouz, Jonas Schreiber, Marion Splittgerber, Thierry Gustot, Laura Weichselbaum, Stanislas Goriely, Eric Trepo, Frédérick Libert, Antonia Lepida, Jishnu Das, Thomas Sersté

Publikováno v: Journal of Hepatology
Journal of Hepatology, Elsevier, 2020, 73, pp.303-314. ⟨10.1016/j.jhep.2020.02.017⟩
Journal of hepatology
Journal of Hepatology, 2020, 73, pp.303-314. ⟨10.1016/j.jhep.2020.02.017⟩

Background & Aims: Severe forms of alcohol-related liver disease are associated with increased susceptibility to infections which are associated with poor prognosis. The cellular and molecular mechanisms responsible for this altered host defense are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90f209e3d5cd3b583f4b4db5a13a6f11
https://hal.archives-ouvertes.fr/hal-03492409

Q-fever associated granulomatous hepatitis

Autor: Thomas Sersté, Maria Gomez Galdon, Isabel Montesinos, Marjan Van Esbroeck, Nicolas Dauby

Publikováno v: International Journal of Infectious Diseases, Vol 95, Iss, Pp 113-114 (2020)
International journal of infectious diseases, 95

SCOPUS: no.j
info:eu-repo/semantics/published

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df90c4e115ef428199a311434c427a66
http://www.sciencedirect.com/science/article/pii/S1201971220302174

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective

Autor: Michel Buset, Marcel Nkuize, Thomas Sersté, Jean-Pierre Mulkay

Publikováno v: Therapeutics and Clinical Risk Management
Therapeutics and clinical risk management, 12

Chronic hepatitis C treatment has continued to evolve, and interferon-free, oral treatment with direct-acting antiviral agents is the current standard of care. Recently, a new treatment, which is a combination of two direct-acting antiviral agents, l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9caa448a7470ecd369426db6f33b6c62
http://europepmc.org/articles/PMC4902143